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Modified-live, Non-adjuvanted Vaccine prior to Intranasal Challenge with
Bovine Herpesvirus-1
Abstract
Study objectives were to determine if subcutaneous administration of a modified-live, non-adjuvanted vaccine
containing bovine herpesvirus-1 (BHV-1) at five, three, or two days pre-challenge, would reduce clinical signs,
rectal temperatures, and viral shedding, and enhance serological response to BHV-1. Colostrumdeprived,
neonatal calves (n = 48) were randomly assigned to six treatment groups, each containing eight calves.
Treatment groups were based on administration of vaccine (VAC) or saline controls (CON) and day of
administration (day -5, -3 or -2) relative to intranasal BHV-1 challenge (day 0). Following challenge, calves
were monitored for clinical signs, rectal temperature, seroconversion, and quantity of BHV-1 recovered by
virus isolation from nasal swabs. Data for the evaluation period (days 4-14) were analyzed using multivariable
statistics. Day -5 and -3 VAC groups had fewer (P < 0.05) days of clinical illness compared to CON. Rectal
temperatures were lower (P < 0.05) during days 4-8 for each of the VAC groups as compared to combined
CON groups. CON calves shed BHV-1 for more days than calves vaccinated on day -5 (P < 0.01), day -3 (P =
0.06), or day -2 (P = 0.06). Mean concentrations of nasal BHV-1 also differed (P < 0.05) between combined
CON groups and each of the VAC groups during at least one study day. Calves in the VAC groups (median =
10 days) seroconverted to BHV-1 (P < 0.01) sooner than CON calves (median = 14 days). This study
demonstrated that the use of a non-adjuvanted MLV vaccine in neonatal calves can reduce the effects of
BHV-1 challenge soon after vaccination.
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Abstract
Study objectives were to determine if subcutane-
ous administration of a modified-live, non-adjuvanted 
vaccine containing bovine herpesvirus-1 (BHV-1) at 
five, three, or two days pre-challenge, would reduce 
clinical signs, rectal temperatures, and viral shedding, 
and enhance serological response to BHV-1.  Colostrum-
deprived, neonatal calves (n = 48) were randomly as-
signed to six treatment groups, each containing eight 
calves.  Treatment groups were based on administration 
of vaccine (VAC) or saline controls (CON) and day of 
administration (day -5, -3 or -2) relative to intranasal 
BHV-1 challenge (day 0).  Following challenge, calves 
were monitored for clinical signs, rectal temperature, 
seroconversion, and quantity of BHV-1 recovered by vi-
rus isolation from nasal swabs.  Data for the evaluation 
period (days 4-14) were analyzed using multivariable 
statistics.  Day -5 and -3 VAC groups had fewer (P < 
0.05) days of clinical illness compared to CON.  Rectal 
temperatures were lower (P < 0.05) during days 4-8 
for each of the VAC groups as compared to combined 
CON groups.  CON calves shed BHV-1 for more days 
than calves vaccinated on day -5 (P < 0.01), day -3 (P = 
0.06), or day -2 (P = 0.06).  Mean concentrations of nasal 
BHV-1 also differed (P < 0.05) between combined CON 
groups and each of the VAC groups during at least one 
study day.  Calves in the VAC groups (median = 10 days) 
seroconverted to BHV-1 (P < 0.01) sooner than CON 
calves (median = 14 days).  This study demonstrated that 
the use of a non-adjuvanted MLV vaccine in neonatal 
calves can reduce the effects of BHV-1 challenge soon 
after vaccination.    
Keywords:  BHV-1, IBR, vaccine, immunity challenge 
studies
Résumé
Les objectifs de l’étude étaient de déterminer si un 
vaccin à virus vivants modifiés sans adjuvant, contenant 
l’herpèsvirus bovin 1 (BHV-1), administré cinq, trois ou 
deux jours avant l’infection expérimentale allait réduire 
les signes cliniques, la température rectale et l’excrétion 
virale tout en rehaussant la réponse sérologique au 
BHV-1. Des veaux nouveau-nés, qui n’avaient pas reçu 
de colostrum, ont été alloués au hasard dans l’un des 
six groupes de traitement chacun contenant huit veaux. 
Les groupes de traitement étaient basés sur la combi-
naison du traitement, soit le vaccin ou soit la saline, 
avec le jour d’administration (jours -5, -3 et -2) relatif 
à l’infection expérimentale par voie intranasale avec 
le BHV-1 au jour 0. Suite à l’infection expérimentale, 
les veaux ont été suivis pour déterminer les signes cli-
niques, la température rectale, la séroconversion et la 
quantité de BHV-1 recouverte par isolation virale dans 
des écouvillons nasaux. Les données pendant la période 
d’évaluation (jours 4 à 14) ont été analysées avec des 
statistiques multivariées. Les individus des groups vac-
cinés au jour -5 et au jour -3 avaient moins (P < 0.05) de 
maladies cliniques par rapport aux veaux témoins. La 
température rectale était moins élevée (P < 0.05) chez 
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les individus de tous les groupes vaccinés que chez les 
veaux témoins durant les jours 4 à 8. Les veaux témoins 
excrétèrent BHV-1 sur une plus longue période que les 
veaux vaccinés au jour -5 (P < 0.01), au jour -3 (P = 0.06) 
ou au jour -2 (P = 0.06). La concentration moyenne de 
BHV-1 dans les écouvillons nasaux différait aussi (P 
< 0.05) entre les groupes témoins combinés et chacun 
des groupes vaccinés au moins pendant une journée de 
l’étude. La séroconversion pour le BHV-1 a pris place 
plus tôt (P < 0.01) chez les individus des groupes vac-
cinés (médiane = 10 jours) que chez les veaux témoins 
(médiane = 14 jours). L’étude démontrait que l’utilisation 
d’un vaccin à virus vivants modifiés sans adjuvant chez 
les veaux nouveau-nés peut réduire les effets d’une infec-
tion expérimentale avec BHV-1 peu après la vaccination. 
Introduction
Bovine respiratory disease (BRD) is a common 
syndrome that affects cattle of all ages.  It is the major 
cause of mortality in weaned dairy heifers15 and an 
extremely important disease complex in beef calves as 
well.2,10 Viral agents commonly involved with BRD in-
clude bovine herpesvirus-1 (BHV-1, causative agent of 
infectious bovine rhinotracheitis) , bovine viral diarrhea 
virus type 1 (BVDV1), bovine viral diarrhea virus type 2 
(BVDV2), bovine respiratory syncytial virus (BRSV), and 
parainfluenza-3 virus (PI-3). Immunizing calves early 
in life against the major viruses involved with the BRD 
complex is one management strategy that veterinar-
ians and producers have chosen to help prevent BRD 
in young calves, and to prime calf immunity for repeat 
inoculations with viral vaccines. 
Despite studies that examined the effects of mod-
ified-live virus (MLV) vaccines on neonatal calves,13,17,18 
there is limited information regarding how early in life, 
and how much in advance of field viral challenge, calves 
need to be vaccinated in order to respond adequately and 
thus be protected at least partially from viruses causing 
BRD.  Bovine fetuses demonstrated antibody and cell 
mediated (basic lymphocyte proliferation) responses to 
tetanus toxoid comparable to adult cattle when those 
fetuses were stimulated with tetanus toxoid in the third 
trimester of gestation.12 As evidenced by a positive pre-
colostral serum neutralization (SN) antibody titer, a 
bovine fetus in the third trimester responded serologi-
cally to BHV-1 virus.8 
Early development of immune responses after 
vaccination is considered important in advance of, and 
during, stressful situations including inclement weather, 
crowded calving or commingling areas, weaning, and 
transport.  Providing early protection against common 
BRD viruses, such as BHV-1, may allow calves to re-
spond more satisfactorily to challenges accompanying 
non-viral stressors.  Numerous studies have verified 
that protection can be elicited soon post-vaccination, as 
early as 24 hours.4,5,14 In one study, calves seronegative 
to BRSV that had positive BRSV-specific T-cell memory 
responded more rapidly (virus-specific IgG, SN antibod-
ies, and T-cell recall) to MLV BRSV vaccination than did 
calves that were both seronegative and T-cell memory-
negative.9  This demonstrated that T-cell responses can 
occur in the absence of an antibody response.9  Previous 
studies have also provided evidence that calves can 
develop protective immune responses following vaccina-
tion, whether or not maternal antibodies are present.7,9,18 
Our study objectives were to determine if subcuta-
neous administration of a modified-live, non-adjuvanted 
vaccine containing BHV-1 at five, three, or two days 
pre-challenge, would reduce clinical signs, rectal tem-
perature, and viral shedding, and enhance serological 
response to BHV-1 in colostrum-deprived calves that 
were 30 days of age or younger.     
Materials and Methods
Animals
Animal handling within this study followed the 
Guide for the Care and Use of Agricultural Animals 
in Agricultural Research and Teaching.  Forty-eight 
colostrum-deprived dairy calves were acquired within a 
day of their birth from a commercial dairy farm located 
approximately 75 miles (120 km) from the study site. 
On the day of birth, ear tags were applied to calves for 
identification purposes.  In addition, ear notches (skin 
biopsies) were tested by immunohistochemistry (IHC) 
for BVDV persistent infection status at a regional di-
agnostic laboratory.a  Cooperators at the dairy farm of 
origin used an esophagogastric tube to feed a commercial 
milk replacerb to calves shortly after their birth.  Calves 
were then bucket-fed two quarts (~two liters) of milk 
replacer twice daily at the cooperating dairy, where they 
remained for no longer than ~24 hours following birth, 
and also at the study site.  Upon arrival at the study 
site, calves were housed in individual huts where they 
remained through the duration of the study.  Calves 
were fed an age-appropriate commercial starter rationc 
beginning at 10 days of age, and hay was fed ad libitum 
starting at one month of age.  Calves were processed 
and managed according to study site standard operat-
ing procedures.  Calves, eight to 30 days old (mean = 
20 days (SD = 5.19)), were randomly assigned to one 
of six treatment groups; randomization was completed 
within blocks defined by birth order, using commercial 
software.d  
Serology 
Blood for BHV-1, BVDV1, BVDV2, and BRSV serol-
ogy was collected from all calves immediately prior to 
administration of vaccine or saline and was submitted to 
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the Iowa State University Veterinary Diagnostic Labo-
ratory, where personnel masked to treatments evalu-
ated the samples per their standard methods.  Serum 
neutralizing antibody titers were determined for BHV-1 
(Colorado strain), BVDV1 (Singer strain), BVDV2 (125A 
strain), and BRSV (A51908 (ATCC VR-794)).  Constant 
virus was incubated with two-fold serial dilutions (1:2-
1:256 for BHV-1, 1:2-1:4096 for BVDV1 and BVDV2, 
and 1:2-1:512 for BRSV) of sera before inoculation of 
Madin-Darbin bovine kidney cells (for BHV-1) or bo-
vine turbinate cells (for BVDV1, BVDV2, and BRSV) in 
microtiter tissue culture plates.  Plates were incubated 
at 98.6°F (37°C) with 5% carbon dioxide for three days 
(BHV-1), five days (BVDV1 and BVDV2), or seven days 
(BRSV) before visual assessment of virus-induced cyto-
pathic effect.  Blood for BHV-1 serology was also collected 
from all calves on day 0 (day of challenge), day 5 or 7, 
and days 10 and 14 post-challenge.  For all samples, 
blood was allowed to clot for approximately two hours, 
and then serum was harvested by centrifuging for 15 
minutes @ 1200 x g.  Serum was split into two aliquots 
and stored in tubes labeled with animal ID and date of 
collection at -4°F (-20°C) until serological evaluation.
Vaccination
Calves received either a commercially available, 
non-adjuvanted modified-live combination vaccinee 
containing BHV-1, BVDV1, BVDV2, PI-3 virus, and 
BRSV subcutaneously (VAC), or saline intranasally 
(CON).  Treatments were administered on day -5 (five 
days before BHV-1 challenge), day -3, and day -2.  On 
each administration day, there were eight calves in VAC 
groups and eight calves in CON groups based on the 
previously described random assignment.  All calves 
were observed daily after vaccination for vaccine-related 
adverse events.
Challenge
On day 0, all calves were challenged intranasally 
with BHV-1f using an atomizer.g  The study was run in 
two study periods with equal numbers of calves, four in 
each treatment group for each study period, in order to 
accommodate the desired number of study animals in 
the research facilities at any one time.  The challenge 
inoculum contained 3.2 x 105.5 TCID50/mL for the chal-
lenge in the first study period.  In order to increase 
clinical expression of disease, the challenge inoculum 
for the second study period was increased to 3.2 x 106.5 
TCID50/mL.  On both challenge dates, 2 mL of challenge 
virus inoculum were atomized into each nares (total 
volume 4 mL/calf).
Post-challenge Observations
Clinical observations were performed daily from 
one day prior to challenge through 14 days after chal-
lenge.  Individuals that performed clinical observations 
were masked (blinded) to treatment assignment.  Each 
calf was visually examined and scored for attitude (scale 
of 0-2), appetite (scale of 0-2), cough (scale of 0-2), fecal 
consistency and/or containing blood (scale of 0-2), nasal 
discharge (scale of 0-4), nasal lesions (scale of 0-2), ocu-
lar discharge (scale of 0-4), ocular lesions (scale of 0-1), 
and respiratory character (scale of 0-2) (Table 1).  The 
absence of a clinical sign was scored as a 0, and a severe 
clinical sign was scored as the highest number for that 
particular clinical sign.
Virus Isolation  
Nasal swabs were collected from all calves on days 
0, 2, 4, 6, 8, 10, 12, and 14.  One polyester-tipped, indi-
vidually packaged, dry, sterile swab, per calf, was used 
to sample both of the calf ’s nares and then placed in a 
cryovial tube (each containing 2 mL of sterile Dulbecco’s 
Modified Eagle Medium) that was marked with the study 
number, calf identification number, date of collection, 
and day of study.  These samples were held at -112°F 
(-80°C) until shipped on dry ice to Intervet/Schering-
Plough Animal Health’s (ISPAH) De Soto, KS facility to 
be assessed for virus quantity by the following described 
methodology.16  All personnel at the ISPAH facility were 
masked to treatment.  Samples from the first study 
period were evaluated over an 11 day period following 
that study period, and samples from the second study 
period were evaluated over an 11 day period following 
that study period.  All samples were diluted 10-fold, and 
each was added to bovine turbinate cell monolayers in 
microtiter tissue culture plates.  Plates were then in-
cubated at 98.6°F for five days with 5% carbon dioxide 
before being evaluated for cytopathic effect.  Plates not 
showing cytopathic effect were fixed with 80% acetone 
and processed for immunofluorescent assay.  Murine 
anti-BHV-1 monoclonal antibody (R54) was added to 
the fixed plates (50 microliters per well) and then incu-
bated for one hour.  After three washes with phosphate 
buffered saline (PBS), fluorine-labeled goat anti-mouse 
IgG was added to the plates which were then incubated 
for another hour.  The plates were then washed three 
more times with PBS and examined under fluorescent 
microscopy.  Samples were considered BHV-1 negative 
if no cytopathic effect or virus-specific fluorescence was 
observed after one blind passage.   
Statistical Analysis    
Data were analyzed with JMPh and SASi software. 
Individual calf was the unit of analysis for all compari-
sons.  Overall, the six treatment groups were based on 
VAC or CON and day of administration (day -5, -3, or 
-2).  Calves were challenged during two periods; there-
fore, study period was evaluated as a potential factor 
(covariate) in statistical analyses.  Prior to statistical 
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Table 1.  Definition of scoring system used for clinical observations of calves challenged with BHV-1.
Clinical observation Scores and descriptions      
     
Attitude 0 = normal, bright,  1 = mild/moderate  2 = severe  
 vigorous and aware  depression, slow  depression, very  
 of surroundings movements and   weak and
  responses,   unable to stand
  reluctant to move      
 
Appetite 0 = normal, calf  1 = reduction in  2 = no feed intake
 anxious to eat feed consumption      
 
Nasal discharge 0 = none 1 = mild/ 2 = severe serous 3 = mild/ 4 = severe purulent
  moderate serous  moderate purulent
Nasal lesions 0 = normal, no 1 = hyperemia of 2 = nasal mucosal
 lesions present nares/muzzle plaques     
  
Ocular discharge 0 = none 1 = mild/ 2 = severe serous 3 = mild/ 4 = severe purulent
  moderate serous  moderate purulent
Ocular lesions 0 = none 1 = plaques/lesions 
  present      
   
Respiratory character 0 = normal 1 = rapid breathing 2 = dyspnea     
  
Cough 0 = none 1 = soft, mild, 2 = harsh, 
  intermittent repetitive cough     
 
Fecal score 0 = normal formed 1 = watery feces 2 = watery or 
 stool  formed with blood     
  
analysis, investigators determined to only analyze data 
collected during a predefined evaluation period (days 4 to 
14 post-challenge).  Since most outcomes were recorded 
multiple times on the same calf, repeated measures 
analyses were performed for such comparisons. Besides 
exceptions described below, data were analyzed using 
general and generalized linear mixed models.  In these 
models, study period was considered as a random effect, 
and a first-order autoregressive correlation structure 
was defined to account for repeated measurements on 
calves over time. Treatment groups were independent 
variables in all analyses.  Contrast statements were used 
for individual pair-wise comparisons when overall treat-
ment effects were observed.  A significance level  of P < 
0.10 was used for all comparisons.  A less conservative 
significance level was used, because sample sizes were 
limited for the specific individual comparisons (e.g., by 
day of vaccine administration) of primary interest. Se-
rology data were normalized prior to analysis.  Data on 
clinical signs could not be appropriately evaluated with 
mixed models; thus, nonparametric permutation tests 
were used to compare means among treatment groups. 
The number of days until an animal stopped shedding 
BHV-1 and the number of days until seroconversion 
occurred were analyzed using nonparametric survival 
analyses and Wilcoxin tests to compare outcomes among 
treatment groups.   
Results
Clinical Signs   
The 48 calves were observed for 11 days during 
the evaluation period (528 calf-days of clinical observa-
tions).  Overall, there were 198 calf-days in which at 
least one clinical sign was observed; most common were 
nasal discharge (n = 176) and ocular discharge (n = 53). 
Clinical signs related to attitude (n =17), appetite (n = 3), 
nasal lesions (n = 0), ocular lesions (n = 0), respiratory 
character (n = 7), cough (n = 4), and fecal score (n = 0) 
were rarely observed.  A daily measure of the presence 
or absence of ≥1 clinical sign and a cumulative sum (for 
each calf) of the number of days with ≥1 clinical sign were 
further evaluated.  Comparisons among CON calves in-
dicated that day of administration (day -5, -3, or -2) was 
not associated with the daily clinical illness measure (≥1 
clinical sign) or the sum of days with ≥1 clinical sign (all 
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Table 2. Comparison of the cumulative number of days when calves were clinically ill (≥1 clinical signs) among treat-
ment groups for the evaluation period (days 4 – 14) following challenge with BHV-1 virus.  Data for Control groups 
were pooled as there were no statistical differences among them.
Treatment groups N Median Mode Mean  P-valuea
    (standard deviation)
Controls  24 5 4 5.17 (2.70) 
Vaccinates day-5 8 2 3 1.875 (1.13) < 0.01
Vaccinates day-3 8 1.5 1 2.25 (2.38) 0.02
Vaccinates day-2 8 5 6 5.13 (2.64) 0.99
aAs compared to Controls; from a nonparametric (permutation) test of means 
P > 0.35).  There were no significant differences in the 
daily number of clinically ill calves between VAC groups 
(day -5, -3, or -2) and CON (all P > 0.50).  However, the 
sum of days in which calves were clinically ill differed 
among groups; the results demonstrating differences in 
the sum of clinically ill days are shown in Table 2.
Differences in the number of clinically ill days 
demonstrated in Table 2 appeared to be largely driven 
by differences in the numbers of days when calves 
had nasal discharge.  CON calves had more days with 
nasal discharge (mean = 5.33 (SD = 3.82)) than calves 
vaccinated at day -5 (mean = 1.5 (SD = 1.2)) and day -3 
(mean = 2.0 (SD = 2.27)), P-values were 0.03 and 0.07 
respectively, but not more (P ~ 1) than day -2 VAC calves 
(mean = 5.25 (SD = 4.68)).  No significant differences 
were observed for comparisons among any other clini-
cal observation data, including data on observed ocular 
discharge (all P > 0.50). 
Rectal Temperature
Rectal temperatures for all VAC and CON calves 
during the evaluation period ranged between 99.3°F 
(37.4°C) and 105.4°F (40.8°C), with a mean and median 
of 101.5°F (38.6°C) and 101.1°F (38.4°C), respectively. 
Rectal temperatures were significantly associated (P 
< 0.05) with treatment groups (vaccine and day of ad-
ministration), day of temperature evaluation, and their 
interactive effects.  Mean rectal temperatures were lower 
(P < 0.01) for all VAC combined as compared to CON, but 
effects varied by administration day (day -5, -3, -2) and 
by day of evaluation (day 4 – 14) (Figure 1).  For CON 
calves, effects varied significantly by evaluation day (P 
< 0.01), but not administration day.  
BHV-1 Shedding 
All animals were shedding virus on day 4 following 
challenge (mean = 6.29 (SD =1.46), median = 6.5; all as 
TCID50/mL).  One calf (CON) was still shedding virus on 
the final sampling day (day 14 post-challenge), whereas 
all other calves had ceased shedding virus by day 14. 
Overall, CON calves shed virus (median = 12 days) sig-
nificantly (P < 0.01) longer than VAC calves (median = 
10 days).  For CON calves, the duration of viral shedding 
was not significantly affected by administration day (P 
< 0.35), but administration day affected shedding for 
VAC calves (P < 0.08).  Calves vaccinated on day -5 (P < 
0.01), day -3 (P = 0.06), or day -2 (P = 0.06) shed virus 
for a shorter duration than CON calves.   The percent 
of calves in the three VAC groups (eight calves/group) 
and three CON groups combined (24 total calves) shed-
ding BHV-1 at each of the six sampling days is depicted 
in Figure 2.
There were significant (P < 0.05) interactions 
among sampling day and treatment groups for viral 
shedding quantities (TCID50/mL).  All VAC calves com-
bined shed significantly less virus (P < 0.01) than CON 
cattle; however, the effects of vaccination varied by day 
of administration and day of nasal swab sampling (P < 
0.01 for interactive effects) (Figure 3).  There were no 
significant differences between different administration 
times for CON calves.  
Serology
Prior to study initiation, none of the study calves 
had detectable antibodies to BRSV, BVDV1, BVDV2, 
and BHV-1, and all were negative for BVDV PI (based 
on pre-study IHC evaluation).  None of the calves had 
detectable antibodies to BHV-1 at day of challenge (day 
0) or by the mid-study monitoring period (days 5-7), 
but there was evidence of seroconversion by day 10.  All 
VAC and all but three CON calves had seroconverted 
by the end of the evaluation period (day 14).  Calves 
in the VAC groups had higher (P = 0.04) titers than 
CON cattle overall (across all sampling days).  How-
ever, there tended to be a significant interaction (P = 
0.07) among sampling day and treatment groups; thus, 
mean titer values for each sampling day and treatment 
group  are displayed in Figure 4.  No significant differ-
ences occurred among administration times (days -5, 
-3, and -2) for CON calves (P-value = 0.90); i.e., the 
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Figure 2.  Percent of calves in each Vaccinate group 
and the three combined Control groups shedding BHV-1 
virus on each sampling day following challenge.  Per-
cent of calves is based on eight calves per group in each 
vaccinate group (one calf = 12.5%), and 24 calves in the 
combined control groups (one calf = 4.2%).  The median 
number of days until BHV-1 shedding ceased tended to 
be greater for calves in the combined Control groups 
than for Vaccinates that were administered vaccine on 
day -5 (P < 0.01), day -3 (P = 0.06), and day -2 (P = 0.06). 
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Figure 3.  Model-adjusteda mean concentration (TCID50/
mL) of BHV-1 isolated from nasal swabs collected from 
Control calves and Vaccinates that were administered 
vaccine on day -5, -3, or -2 prior to BHV-1 challenge. 
Means for Vaccinates that differed statistically (P < 0.05) 
from means for Controls within the same sampling day 
are designated by .
aFrom linear mixed model with a first order autocorre-
lation structure to adjust for repeated observations on 
calves within groups.
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Figure 4.  Meana antibody titer values for BHV-1 over 
the period of evaluation for Control calves and Vacci-
nates that were administered vaccine on day -5, -3, or 
-2 prior to BHV-1 challenge.  Means for Vaccinates that 
differed statistically (P < 0.05) from means for Control 
calves within the same sampling day are designated 
by .
aFrom a linear mixed model with an autocorrelation 
structure to adjust for repeated observations on calves 
within groups.  Data for titer values were normalized 
for analysis. 
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Figure 1.  Model-adjusteda mean rectal temperatures 
for Controls and Vaccinates that were administered vac-
cine containing BHV-1 on day -5, -3, or -2 (prior to BHV-1 
challenge).  Means that differed statistically (P < 0.05) 
from Control means within day are designated by . 
aFrom a linear mixed model with a random effect for 
study period and a first order autocorrelation structure 
to adjust for repeated observations on calves within 
groups.
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timing of saline administration had no effect on BHV-1 
antibody titer values.   
The probability of seroconversion by day 14 did 
not differ statistically among treatment groups or study 
periods (P-values > 0.90).  However, treatment group 
(VAC or CON) was significantly associated (P < 0.01) 
with the time period (day) at which seroconversion oc-
curred.  The day of product administration (-5, -3, or -2) 
did not significantly affect time of seroconversion when 
comparing among VAC (P = 0.22) or among CON calves 
(P = 0.13).  However, all VAC calves combined (median 
= 10 days) seroconverted (P < 0.01) sooner than CON 
calves (median = 14 days).   
Discussion
Vaccination of neonatal calves is widely practiced 
in the US dairy and beef industries, and many early vac-
cinations are intended to help prevent and control BRD. 
Despite the fact that appropriate vaccinations adminis-
tered well in advance of pathogen insult is championed 
as a means of reducing BRD, beef and dairy producers 
may not provide calves sufficient time to respond to vac-
cines prior to pathogen challenge.  Dairy calves may be 
relocated to another farm and commingled with other 
calves on the day of birth, without the advantages of 
adequate colostral intake and preventive vaccinations. 
Beef calves are often abruptly weaned, transported to 
auction markets where they are commingled with other 
calves, and transported to central gathering points. 
Further commingling is common, and calves may or 
may not be vaccinated prior to transport to a stocker 
operation or feedlot.  In this situation, it is important 
that vaccines intended to prevent BRD provide a rapid 
protective immune response.
There is limited information on the response of 
neonatal calves to virus vaccines, and the length of time 
it takes neonatal calves to develop immunity following 
vaccination.  Calves in the present study were less than 
30 days of age when vaccinated with a non-adjuvanted, 
multivalent virus vaccine containing BHV-1.  When 
challenged with BHV-1 two, three, or five days follow-
ing vaccination, clinical signs of BHV-1 infection were 
lessened in calves vaccinated five or three days prior to 
the challenge as compared to controls.  Calves in all VAC 
groups had lower rectal temperatures, less shedding of 
BHV-1, and higher SN titers to BHV-1 than calves in the 
CON groups.  BHV-1 experimental challenges typically 
cause relatively subtle signs of disease.  It was deemed 
advantageous to increase the challenge level of BHV-1 
virus for the second period of the study in order to further 
demonstrate differences in clinical signs and incidence 
of BHV-1 virus isolation between treatments.
These calves were colostrum deprived, not unlike a 
significant proportion of dairy calves in the US.15  In an 
earlier study, the MLV vaccine used in this study elicited 
cell-mediated immune (CMI) responses in three- to four-
month old calves,6 but the CMI response to this product 
has not been studied in calves less than 30 days of age. 
Further evidence of the ability of CMI to protect young 
calves was evident in another study after maternal an-
tibodies had been depleted prior to a BVDV type 2 chal-
lenge.3  Although the CMI response was not measured 
in the present study, it is possible that CMI contributed 
to the protection afforded the vaccinated calves.  
Originally, 72 calves were included in the study. 
However, 24 calves administered an intranasal vaccinej 
were not included in the analysis because the vaccine 
is no longer marketed.  Intranasal saline was selected 
as the control for both the intranasalj and subcutane-
ous vaccinatee groups (data on the former not shown). 
In retrospect, the decision to administer saline by 
the intranasal route to the control calves rather than 
subcutaneously (same route as vaccinated group) was 
less than optimal, but that decision was made when 
calves vaccinated with the intranasal vaccine were to 
be included in the analysis.  However, administration of 
saline, regardless of route, provides for a suitable control 
as it is physiologically neutral, and has been used in 
other vaccine studies.11,17,18  
An option for future studies is to delete the BHV-1 
antigen from the multivalent test vaccine for use as the 
control product.  By doing so, the control would differ 
from the test vaccine by only a single parameter, thus 
minimizing potential clinical or immunological differ-
ences caused by other antigens or extraneous material 
in the vaccine.
Space constraints at the study site dictated that 
the study be conducted in two periods and to limit the 
total number of animals during each of the two study 
periods to maintain adequate biosecurity and separa-
tion of individual calves, as well as separation of VAC 
calves from CON.  By utilizing two study periods, we 
were able to include more calves per treatment group, 
thereby increasing statistical power to demonstrate any 
differences in outcomes.  
A four-fold increase in antibody titer is commonly 
accepted as an indicator that a calf has responded se-
rologically to a virus.1  The mean BHV-1 SN titers for 
VAC were not four-fold greater than CON during the 14 
day post-challenge period; however, statistical analysis 
demonstrated that VAC calves developed higher mean 
titers than did CON.  BHV-1 virus does not typically 
stimulate production of high antibody titers, and the 
relatively low titers at 10 and 14 days post-challenge are 
not surprising.  The purpose of measuring the serological 
response was not necessarily to demonstrate a four-fold 
or greater seroconversion, but rather to evaluate differ-
ences between treatments.  In spite of the short time 
from vaccination to BHV-1 challenge, results demon-
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strated that calves in the VAC groups had been sensi-
tized by vaccination, and were able to mount a higher 
mean antibody response post-challenge as compared to 
calves in the CON groups.  It can be argued that two-fold 
titer changes, e.g. 1:2 to 1:4, are not biologically different 
due to inherent characteristics of SN testing, but means 
for the VAC treatment groups were statistically differ-
ent than those of the CON (multiple titer evaluations), 
thus, the data are meaningful for comparative purposes.
Conclusions and Clinical Relevance
This study demonstrated that using one dose of 
a non-adjuvanted MLV vaccine in colostrum-deprived 
calves less than 30 days of age when vaccinated five, 
three, or two days in advance of a direct BHV-1 chal-
lenge, reduced viral shedding and rectal temperature 
as compared to non-vaccinated animals.  Additionally, 
clinical signs of IBR were reduced in calves vaccinated 
five days or three days before challenge, and those same 
calves developed higher SN mean titers to BHV-1 by 10 
days post-challenge than did non-vaccinates.  The rapid 
protective immune response observed in calves averag-
ing 20 days of age suggests that vaccinating with this 
non-adjuvanted MLV vaccine could be beneficial when 
a quick immune response is crucial. 
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